This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Auna S.A. (AUNA) Reports Next Week: What You Should Expect
by Zacks Equity Research
Auna S.A. (AUNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUNAPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Home Depot (HD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Home Depot (HD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SYREPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TECXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Treace Medical Concepts (TMCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TMCINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 51.77% Upside in Inspired Entertainment (INSE): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 51.8% upside potential for Inspired Entertainment (INSE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
INSEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Intapp (INTA) Could Rally 26.09%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Intapp (INTA) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
INTANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Honest (HNST) Climb 40.83% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Honest (HNST) points to a 40.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HNSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Kemper (KMPR) Have the Potential to Rally 25.46% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Kemper (KMPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
KMPRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MNMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Centrus Energy (LEU) Could Surge 56.61%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Centrus Energy (LEU) points to a 56.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LEUPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TXGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Easterly Government Properties (DEA) Climb 35.04% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 35% upside potential for Easterly Government Properties (DEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DEAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think AudioEye (AEYE) Could Surge 73.64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 73.6% upside potential for AudioEye (AEYE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AEYENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 156.09% Upside in Beyond (BYON): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 156.1% upside potential for Beyond (BYON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BYONNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 36.55% Upside in Ardent Health Partners, Inc. (ARDT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Ardent Health Partners, Inc. (ARDT) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ARDTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Clearfield (CLFD)? Wall Street Analysts Think 26.51%
by Zacks Equity Research
The mean of analysts' price targets for Clearfield (CLFD) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CLFDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CLPTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
COGTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BBIOPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 57.47% Upside in Abacus Life, Inc. (ABL): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 57.5% upside potential for Abacus Life, Inc. (ABL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ABLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BLFSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
ZIM Integrated Shipping Services (ZIM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
ZIM (ZIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZIMNegative Net Change SBLKNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
ICL Group (ICL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ICL Group (ICL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICLNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe IonQ (IONQ) Could Rally 27.92%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for IonQ (IONQ) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IONQPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate